ACIU's Phase II Trial Meets Safety and Immunogenicity Goals
核心洞察
AC Immune reported that ACI-7104 met its primary safety and immunogenicity endpoints in a Phase 2 trial in patients with early Parkinson's disease (搜索).
All treated patients in the study developed robust antibody responses, and no significant safety concerns were observed with the vaccine candidate.
Exploratory analyses suggested a link between antibody levels and clinical outcomes, supporting expansion into a larger Phase 2 study.
AC Immune SA reported that ACI-7104 met its primary safety and immunogenicity endpoints in a Phase 2 trial conducted in patients with early Parkinson's disease (搜索). All treated patients developed robust antibody responses, and no significant safety concerns were identified.
Exploratory analyses from the trial suggest a link between antibody levels and clinical outcomes. According to the company, those signals support further development of the candidate and expansion into a larger Phase 2 study.
The results were disclosed in AC Immune slides released on September 23, 2026.